Plexxikon Wins Tafinlar Patent Dispute Case Against Novartis
Executive Summary
The Daiichi Sankyo affiliate successfully argued that Novartis willfully infringed two patents covering its discoveries in the BRAF inhibitor drug class, getting nearly $178m in damages and future royalties.